Paul Sanger interviewed Damian Spring, CEO of Santana Minerals Limited (ASX:SMI), to discuss the Bendigo gold project, which has recently been designated as a fast-track project. Damian highlighted the project's economic potential, projecting 1.1 million ounces of gold over ten years, which could generate significant export earnings and job creation in New Zealand. He mentioned ongoing environmental studies and a feasibility study set for release soon, emphasising the positive impact of rising gold prices on profitability and investor interest.
Copyright 2024 – Finance News Network
21 Sep 2023 - Phil McNamara - Director - Emperor Energy (ASX:EMP) is a diversified energy company with upstream and downstream assets in Australia. The company’s strategic asset Vic/P47 in the Gippsland Basin next to the BHP/ExxonMobil Kipper field.
29 Sep 2023 - Vital Metals Limited (ASX:VML) Interim Non-Executive Chairman Richard Crookes discusses termination of the company's Saskatoon facility, the Tardiff rare earths asset, and next steps for the company.
20 Sep 2019 - Prospect Resources Limited (ASX:PSC) Managing Director, Sam Hosack provides an update on the company's Arcadia lithium project in Zimbabwe, including advanced negotiations with a number of African and international banks on funding.
10 Oct 2023 - Jon Price - Managing Director - Richmond Vanadium Technology (ASX:RVT) is an Australian minerals development company which is advancing the Richmond – Julia Creek Vanadium Project in Queensland through a Bankable Feasibility Study.
06 Nov 2019 - Immutep Limited (ASX:IMM) CEO, Marc Voigt provides an update on the company's clinical trial data for its Phase 1 trial in melanoma, TACTI-mel, where patients are responding positively to the combination therapy of efti and Keytruda.
18 Apr 2024 - Anax Metals (ASX:ANX) CEO Geoff Laing discusses the company's innovative approach to mining as its pioneers bioleaching tech for sustainable resource extraction.
29 Sep 2022 - Arovella Therapeutics Limited (ASX:ALA) Managing Director and CEO Michael Baker discusses the company's collaboration with Imugene to combine therapies.
